Be on our

Show

To be a part of BuxMont Live Sign up Now!
icon-1
 

Promote your

Event

Tell Us and We’ll Read it On Air.

icon-3

Bring the

Music

Share your music on BuxMont Live radio

icon-4

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)

Written by John Ralston on . Posted in Uncategorized

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)PHILADELPHIA, Oct. 28, 2019 /PRNewswire/ — SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company’s novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC).

Tags: